Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) [Phase 1, Phase 2]
A clinical trial update indicates the Phase 1/2 study of KB-0742 in relapsed or refractory solid tumors, including platinum-resistant high-g…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma [Phase 2, Phase 3]
A Phase 2/3 clinical trial of NKTR-255 after CD19-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies [Phase 1, Phase 2]
A first-in-human study of the investigational agent 1A46 in advanced CD20/CD19-positive B-cell hematologic malignancies has been terminated;…
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma [Phase 1]
A terminated Phase 1 trial from Stanford evaluated the PET imaging tracer 18F-F-AraG to assess immunological response to CAR T cell therapy …
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL [Phase 1, Phase 2]
Phase 1/2 trial evaluating anti-CD19 CAR T cells in pediatric patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-H…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating siltuximab to prevent CAR T cell–related cytokine release syndrome in CD19-positive non-Hodgkin lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients [Phase 2, Phase 3]
Completed Phase 2/Phase 3 trial evaluating nivolumab with gemcitabine, oxaliplatin, and rituximab in elderly patients with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients [Phase 4]
Phase 4 study evaluating outcomes of early versus late G-CSF administration for primary prophylaxis in patients with non-Hodgkin's lymphoma …
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma Patients [NA]
The clinical trial evaluating a decision support system for symptom self-management in Non-Hodgkin lymphoma patients has completed.
-
CLINICAL_TRIALS trial_result · 2025-01-24Clinical Trial Update: A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies [EARLY_Phase 1]
A Phase 1 study evaluating CTA30X cell injection in relapsed or refractory CD19-positive B-line hematological malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL [Phase 1]
Phase 1 study evaluating glofitamab in combination with either rituximab or obinutuzumab plus CHOP, or polatuzumab vedotin plus rituximab wi…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma [Phase 1]
Phase 1/2 study of AZD0466 in advanced Non-Hodgkin Lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results w…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 1]
This Phase 1 trial assessed safety, tolerability, and maximum tolerated dose of BI 2536 in patients with recurrent advanced aggressive non-H…
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma [Phase 1]
Phase 1 trial testing EBV-specific cytotoxic T cells in relapsed EBV-positive lymphomas has completed, assessing safety and preliminary acti…
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: CAR-37 T Cells in Hematologic Malignancies [Phase 1]
Phase 1 trial update on CAR-37 T cells in hematologic malignancies shows the study has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL [Phase 1]
Phase 1 trial update evaluating safety, PK/PD, and clinical activity of KT-413 in adults with relapsed or refractory B-cell non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma [Phase 3]
Phase 3 clinical trial update on managing pain and chemotherapy-related symptoms in people with multiple myeloma or lymphoma, with results p…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) [Phase 1]
Phase 1 PANAMA trial evaluating a dual NAMPT/PAK4 inhibitor in patients with solid tumors or non-Hodgkin lymphoma was terminated, with resul…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A [Phase 3]
Results from a Phase 3 safety study of subcutaneous rituximab in CD20-positive diffuse large B-cell lymphoma or CD20-positive follicular lym…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: MB-CART20.1 Lymphoma [Phase 1, Phase 2]
Miltenyi Biomedicine's MB-CART20.1 Lymphoma trial in relapsed or refractory B-cell non-Hodgkin lymphoma and non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China [Phase 1]
Phase 1 clinical trial update evaluating Maplirpacept in advanced non-Hodgkin lymphoma or multiple myeloma in China has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) [Phase 1, Phase 2]
A Phase 1/Phase 2 trial of APR-246 in combination with acalabrutinib or venetoclax in relapsed/refractory non-Hodgkin lymphoma has been term…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies [Phase 1, Phase 2]
Update on the completed Phase 1/2 study of ZX-101A assessing activity, safety, and tolerability in relapsed/refractory hematological maligna…